sorafenib has been researched along with acetazolamide in 6 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (acetazolamide) | Trials (acetazolamide) | Recent Studies (post-2010) (acetazolamide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7,604 | 495 | 1,521 |
| Protein | Taxonomy | sorafenib (IC50) | acetazolamide (IC50) |
|---|---|---|---|
| Chain A, Class Iii Chitinase Chia1 | Aspergillus fumigatus A1163 | 164 | |
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.3178 | |
| Renin | Homo sapiens (human) | 8.2 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 2.3173 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 1.2619 | |
| Carbonic anhydrase 2 | Bos taurus (cattle) | 0.7 | |
| Carbonic anhydrase 3 | Homo sapiens (human) | 1.95 | |
| Cathepsin B | Bos taurus (cattle) | 0.02 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.025 | |
| Carbonic anhydrase 4 | Homo sapiens (human) | 0.1216 | |
| Carbonic anhydrase 6 | Homo sapiens (human) | 0.2925 | |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | 0.1763 | |
| Carbonic anhydrase 7 | Homo sapiens (human) | 1.1737 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.464 | |
| Renin | Macaca mulatta (Rhesus monkey) | 8.2 | |
| Carbonic anhydrase 13 | Homo sapiens (human) | 0.23 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.07 | |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | 0.77 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.183 | |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | 0.23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdel-Aziz, HA; Abo-Ashour, MF; Al-Rashood, ST; Bonardi, A; Bua, S; El-Haggar, RS; Eldehna, WM; Gratteri, P; Hassan, GS; Nocentini, A; Supuran, CT | 1 |
| Al-Tamimi, AS; Angeli, A; Bozdag, M; Bua, S; Carta, F; Ferraroni, M; Kunkler, IH; Langdon, SP; Supuran, CT; Ward, C | 1 |
| Huwaimel, BI; Jonnalagadda, S; Mikelis, CM; Nocentini, A; Supuran, CT; Trippier, PC; Zahra, FT | 1 |
| Alsaab, HO; Alzhrani, RM; Cheriyan, VT; Iyer, AK; Polin, LA; Rishi, AK; Sau, S; Vaishampayan, U | 1 |
1 review(s) available for sorafenib and acetazolamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for sorafenib and acetazolamide
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Catalytic Domain; Cell Cycle; Cell Line, Tumor; Humans; Hydrophobic and Hydrophilic Interactions; Isatin; Molecular Docking Simulation; Phenylurea Compounds; Protein Binding; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbonic Anhydrase Inhibitors; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Models, Molecular; Molecular Structure; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation.
Topics: Angiogenesis Inhibitors; Benzothiadiazines; Cell Movement; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Phosphorylation; Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Topics: Acetazolamide; Animals; Antineoplastic Agents; Apoptosis; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cellular Reprogramming; Combined Modality Therapy; Drug Carriers; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Kidney Neoplasms; Macrophages; Mice; Mice, Nude; Nanoparticles; Permeability; Proof of Concept Study; Sorafenib; Theranostic Nanomedicine; Tumor Hypoxia | 2018 |